Since CTI BioPharma Corp. (NASDAQ:CTIC) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CTI BioPharma Corp.	12.28M	4.36	44.51M	-0.87	0.00
ZIOPHARM Oncology Inc.	1.74M	235.88	75.56M	-0.54	0.00

Table 1 showcases the gross revenue, earnings per share and valuation of CTI BioPharma Corp. and ZIOPHARM Oncology Inc.

Profitability

Table 2 shows CTI BioPharma Corp. and ZIOPHARM Oncology Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CTI BioPharma Corp.	-362.46%	-77.4%	-49.1%
ZIOPHARM Oncology Inc.	-4,342.53%	58.6%	-89.9%

Volatility & Risk

CTI BioPharma Corp. is 141.00% less volatile than Standard and Poor’s 500 due to its -0.41 beta. ZIOPHARM Oncology Inc. has a 1.91 beta and it is 91.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of CTI BioPharma Corp. are 3.6 and 3.6 respectively. Its competitor ZIOPHARM Oncology Inc.’s Current Ratio is 0.8 and its Quick Ratio is 0.8. CTI BioPharma Corp. can pay off short and long-term obligations better than ZIOPHARM Oncology Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for CTI BioPharma Corp. and ZIOPHARM Oncology Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
CTI BioPharma Corp.	0	0	0	0.00
ZIOPHARM Oncology Inc.	0	0	1	3.00

Competitively the consensus price target of ZIOPHARM Oncology Inc. is $5, which is potential 94.55% upside.

Institutional & Insider Ownership

The shares of both CTI BioPharma Corp. and ZIOPHARM Oncology Inc. are owned by institutional investors at 62.1% and 41.4% respectively. 0.1% are CTI BioPharma Corp.’s share held by insiders. Comparatively, 1.77% are ZIOPHARM Oncology Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CTI BioPharma Corp.	-11.9%	-14.45%	-23.32%	-69.86%	-43.94%	-44.78%
ZIOPHARM Oncology Inc.	-8.06%	24.7%	14.07%	-29.52%	-29.03%	-25.6%

For the past year CTI BioPharma Corp.’s stock price has bigger decline than ZIOPHARM Oncology Inc.

Summary

CTI BioPharma Corp. beats on 6 of the 11 factors ZIOPHARM Oncology Inc.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.